The "Cold, Hard, Facts" about GTC....
The annual stockholder meeting in 2006 was a pretty gloomy affair. The EMEA had unexpectedly given the company a negative opinion and the share price dropped 50% and there was alot of worry about a possible cheap buyout. I talked to Christian B. CEO of LBF who was there and asked him in private if LFB would defend GTC against a takeover. His very words were, "LFB would not act as a White Knight". Little did I guess that later it might be LFB in the role of the raider.
The way I see it, GTC is not well situated to bringing truly novel biotherapeutics to the market. The drug industry-FDA game is rigged against them as described in several of my previous posts. The FOB situations are unclear at the present and will be heavily dependent on how the FDA decides where and if transgenic production can substitute for cell culture. That leaves plasma proteins.
There are well over a hundred plasma protiens and the potential profits are mind boggling. In this game, GTC's NPPP holds all the Aces. They face two problems... The first one is the difficulty of expressing plasma proteins in cell culture and their availability in pooled plasma, although limited, has meant relatively few BPs have done much business with them,,ergo they are outside of most of BPs interest. BP executives are not renown for their abilities to think "outside the box". The other problem is LFB who is in the plasma protien business and clearly understands how important GTC's NPPP is, and also understands how desperate things are at GTC. To me it looks like an alligator dragging one of my kids into a swamp.
I wish I knew a a way to wake up Mass or the government so ready to throw trillions into the rotten financial mess,,to put up a couple hundred million to save this valuable resource. Perhaps someone on this board could come up with an idea.
JL
AI
Market Data 
Markets 
